BioNTech SE Sponsored ADR $BNTX Stake Raised by Privium Fund Management B.V.

Privium Fund Management B.V. raised its holdings in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX) by 72.9% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 19,000 shares of the company’s stock after acquiring an additional 8,013 shares during the quarter. Privium Fund Management B.V.’s holdings in BioNTech were worth $1,874,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in BNTX. Dodge & Cox acquired a new stake in shares of BioNTech during the second quarter worth approximately $93,421,000. Bank of New York Mellon Corp lifted its position in BioNTech by 58.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 1,108,719 shares of the company’s stock worth $118,045,000 after buying an additional 410,351 shares in the last quarter. Aberdeen Group plc boosted its stake in shares of BioNTech by 87.2% during the 2nd quarter. Aberdeen Group plc now owns 721,928 shares of the company’s stock valued at $76,864,000 after buying an additional 336,260 shares during the period. Franklin Resources Inc. grew its holdings in shares of BioNTech by 76.8% during the 2nd quarter. Franklin Resources Inc. now owns 751,998 shares of the company’s stock valued at $80,065,000 after acquiring an additional 326,556 shares in the last quarter. Finally, TD Asset Management Inc grew its holdings in shares of BioNTech by 1,417.6% during the 2nd quarter. TD Asset Management Inc now owns 173,795 shares of the company’s stock valued at $18,513,000 after acquiring an additional 162,343 shares in the last quarter. 15.52% of the stock is owned by hedge funds and other institutional investors.

BioNTech Trading Down 2.6%

Shares of BNTX stock opened at $113.75 on Friday. BioNTech SE Sponsored ADR has a 12 month low of $81.20 and a 12 month high of $124.98. The company has a market cap of $25.61 billion, a PE ratio of -43.25 and a beta of 1.40. The company has a quick ratio of 7.02, a current ratio of 7.12 and a debt-to-equity ratio of 0.01. The business’s 50 day moving average is $101.09 and its two-hundred day moving average is $103.89.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings data on Monday, November 3rd. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.75 by ($0.89). BioNTech had a negative return on equity of 3.03% and a negative net margin of 17.91%.The firm had revenue of $1.78 billion for the quarter, compared to the consensus estimate of $1.21 billion. During the same period in the prior year, the company posted $0.81 earnings per share. BioNTech’s quarterly revenue was up 22.0% on a year-over-year basis. Equities analysts predict that BioNTech SE Sponsored ADR will post -3.88 EPS for the current year.

Analysts Set New Price Targets

A number of research firms recently issued reports on BNTX. UBS Group raised BioNTech to a “hold” rating in a research report on Thursday, December 4th. Berenberg Bank reaffirmed a “buy” rating on shares of BioNTech in a research note on Friday, January 23rd. The Goldman Sachs Group raised BioNTech from a “neutral” rating to a “buy” rating and boosted their price target for the company from $115.00 to $142.00 in a research note on Friday, January 16th. Bank of America dropped their price objective on BioNTech from $134.00 to $130.00 and set a “buy” rating on the stock in a report on Wednesday, October 22nd. Finally, HC Wainwright reiterated a “buy” rating and issued a $140.00 target price on shares of BioNTech in a research note on Thursday, December 11th. Eleven equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $140.03.

About BioNTech

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.